Trial · NCT07405190
Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC
NCT07405190, Phase 2, Recruiting, Massachusetts General Hospital
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC. Trials, record NCT07405190. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07405190
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC
- NCT number
- NCT07405190
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 46 participants, estimated
- Lead sponsor
- Massachusetts General Hospital
- Conditions
- Lung Cancer (NSCLC), Lung Cancer Non-Small Cell Cancer (NSCLC), Lung Cancer (Non-Small Cell), Lung Cancer - Non Small Cell, Lung Cancer Non Small Cell, Genomic Alterations
- Interventions
- Ivonescimab, carboplatin, pemetrexed
- First posted
- 2026-02-12
- Last updated
- 2026-07-15
Source ClinicalTrials.gov
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective Response Rate (ORR) of Ivonescimab Monotherapy | Day 1 of cycle 1 (each cycle is 21 days) to disease progression, loss of follow-up, withdrawal of consent, study termination, or for up to 2 years from the day the last patient is enrolled, whichever occurs first. | The objective response rate (ORR) is defined as the number of patients with confirmed best overall response or complete response or partial response (PR) divided by the number of treated patients in the cohort. ORR will be measured per investigator. BOR will be assessed per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) criteria. |
| Primary | Objective Response Rate (ORR) of Ivonescimab plus Carboplatin/Pemetrexed | Day 1 of cycle 1 (each cycle is 21 days) to disease progression, loss of follow-up, withdrawal of consent, study termination, or for up to 2 years from the day the last patient is enrolled, whichever occurs first. | The objective response rate (ORR) is defined as the number of patients with confirmed best overall response or complete response or partial response (PR) divided by the number of treated patients in the cohort. ORR will be measured per investigator. BOR will be assessed per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) criteria. |
| Secondary | Disease Control Rate (DCR) of Ivonescimab Monotherapy | Day 1 of cycle 1 (each cycle is 21 days) to disease progression, loss of follow-up, withdrawal of consent, study termination, or for up to 2 years from the day the last patient is enrolled, whichever occurs first. | Disease control rate (DCR) is defined as the percentage of participants who have either a complete response, partial response, or stable disease. DCR will be assessed per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) criteria. |
| Secondary | Disease Control Rate (DCR) of Ivonescimab plus Carboplatin/Pemetrexed | Day 1 of cycle 1 (each cycle is 21 days) to disease progression, loss of follow-up, withdrawal of consent, study termination, or for up to 2 years from the day the last patient is enrolled, whichever occurs first. | Disease control rate (DCR) is defined as the percentage of participants who have either a complete response, partial response, or stable disease. DCR will be assessed per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) criteria. |
| Secondary | Time to Response (TTR) of Ivonescimab Monotherapy | Day 1 of cycle 1 (each cycle is 21 days) to the first documentation of complete or partial response for up to 2 years from the day the last patient is enrolled. | Time to response (TTR) is defined as the amount of time between the first dose of ivonescimab to the first time that measurement criteria are met for complete response or partial response. TTR will be assessed per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) criteria. |
| Secondary | Time to Response (TRR) of Ivonescimab plus Carboplatin/Pemetrexed | Day 1 of cycle 1 (each cycle is 21 days) to the first documentation of complete or partial response for up to 2 years from the day the last patient is enrolled. | Time to response (TTR) is defined as the amount of time between the first doses of ivonescimab, carboplatin, and pemtrexed to the first time that measurement criteria are met for complete response or partial response. TTR will be assessed per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) criteria. |
| Secondary | Duration of Response (DOR) of Ivonescimab Monotherapy | First day complete or partial response is recorded to the first day progressive disease is recorded or, if no progressive disease occurs, the date of last radiological assessment up to 2 years from the day the last patient is enrolled. | Duration of response (DOR) is defined as the amount of time from the first recording of complete or partial response (whichever is recorded first) to the first date that progressive disease is objectively documented. DOR will be assessed per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) criteria. Patients who do not achieve at least a partial response, will be excluded from the analysis of DOR. |
| Secondary | Duration of Response (DOR) of Ivonescimab plus Carboplatin/Pemetrexed | First day complete or partial response is recorded to the first day progressive disease is recorded or, if no progressive disease occurs, the date of last radiological assessment up to 2 years from the day the last patient is enrolled. | Duration of response (DOR) is defined as the amount of time from the first recording of complete or partial response (whichever is recorded first) to the first date that progressive disease is objectively documented. DOR will be assessed per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) criteria. Patients who do not achieve at least a partial response, will be excluded from the analysis of DOR. |
| Secondary | Progression-Free Survival (PFS) of Ivonescimab Monotherapy | Day 1 of cycle 1 (each cycle is 21 days) to the first day of documented disease progression, death, or if no disease progression or death occurs, the day of the last radiological assessment, up to 2 years from the day the last patient was enrolled. | Progression-free survival (PFS) is defined as the time from the start date of the study drug treatment to the date of first documented progression or death due to any cause. PFS will be assessed will be assessed per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) criteria. PFS will be summarized using the Kaplan-Meier method with median PFS time (including two-sided 95% confidence interval (CI)). The PFS rates at 6 months and at 12 months will be estimated with two-sided 95% CIs. |
| Secondary | Progression-Free Survival (PFS) of Ivonescimab plus Carboplatin/Pemetrexed | Day 1 of cycle 1 (each cycle is 21 days) to the first day of documented disease progression, death, or if no disease progression or death occurs, the day of the last radiological assessment, up to 2 years from the day the last patient was enrolled. | Progression-free survival (PFS) is defined as the time from the start date of the study drug treatment to the date of first documented progression or death due to any cause. PFS will be assessed will be assessed per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) criteria. PFS will be summarized using the Kaplan-Meier method with median PFS time (including two-sided 95% confidence interval (CI)). The PFS rates at 6 months and at 12 months will be estimated with two-sided 95% CIs. |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07405190
GET https://conductscience.org/api/trials/v1/NCT07405190/registered